Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-02. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
=== Sandia National Laboratories and implantable insulin pump development === In parallel with early academic and commercial efforts, significant development of implantable insulin delivery systems was carried out at Sandia National Laboratories in collaboration with the University of New Mexico School of Medicine during the late 1970s and early 1980s. This work focused on the design of an electronically controlled, remotely programmable insulin infusion system intended to more closely replicate the physiological function of the human pancreas. The Sandia–UNM system built upon earlier external insulin pumps and incorporated engineering approaches derived from high-reliability systems, including precise flow control and programmable delivery rates. The implantable device was tested in animal models and subsequently implanted in human patients beginning in January 1981, with additional implantations reported in early 1982. Key engineering contributions to the system were made by a multidisciplinary team at Sandia, including Gary A. Carlson, Raymond E. Bair, John I. Gaona Jr., Jerry T. Love, and Ruben S. Urenda, who co-authored foundational technical reports describing the design and operation of the implantable, remotely programmable insulin infusion system. Earlier engineering work on insulin delivery systems by members of the Sandia–UNM collaboration was also described in peer-reviewed literature, including analysis of system design considerations such as flow control, programmability, and reliability.
The ease with which our potatoes lend themselves to all sorts of stews gave me the idea of composing a meal of them, to which I invited several amateurs; and at the risk of being thought to be afflicted with potato mania, I will end this review by describing it: it was a dinner. We were first served two soups, one of mashed potatoes from our roots, the other of a fatty broth, in which the potato bread simmered quite well without crumbling; then came a matelote followed by a dish in white sauce, then another in maitre d'hôtel, and finally a fifth in roux. The second service consisted of five other dishes not less good than the first; first a pâté, a frying, a salad, fritters, and the economic cake of which I gave the recipe; the remainder of the meal was not very extensive, but delicate and good; a cheese, a pot of jam, a plate of cookie, another of tarts, and finally a brioche also of potatoes, made up the dessert; after that we had the coffee, also described above. There were two kinds of bread; the one mixed with potato pulp and wheat flour, fairly represented soft bread; the second, made of potato pulp, with their starch, bore the name of firm dough bread; I would have wished that fermentation had put me in a position to make a drink of our roots, to fully satisfy my guests, and to say with foundation: "Do you like potatoes, we have put them everywhere." Every one was cheerful; and if potatoes are drowsy, they produce on us a very opposite effect.
As an actor, Ice-T played small parts in the films Breakin' (1984) and its sequels, Breakin' 2: Electric Boogaloo and Rappin' (1984 and 1985 respectively), before his major role debut, starring as police detective Scotty Appleton in New Jack City (1991). He received top billing for his role in Surviving the Game (1994) and continued to appear in small roles in TV series and other films throughout the 1990s. Since 2000, he has portrayed NYPD detective/sergeant Odafin Tutuola on the NBC police drama Law & Order: Special Victims Unit, making him the longest-running male series actor in American TV history, according to Deadline. A reality television show titled Ice Loves Coco ran for three seasons (2011–2013) on E!, featuring the home life of Ice-T and his wife Coco Austin. In 2018, he began hosting the true crime documentary In Ice Cold Blood on the Oxygen cable channel, which ran for three seasons.
Sources: en.wikipedia.org
The Trump administration informs Congress that it is sending over $206 million for International Stabilization Force. Iran war: The US military states that it carried out dozens of retaliatory strikes targeting the IRGC in Iran. Cyberwarfare during the Iran War: Minnesota IT Services reports a cyberattack across 30 municipal community water systems in Minnesota, with authorities believing Iranian hackers were probably responsible. The water supply is found to still be safe to drink. July 31 2026 Iran war: Trump states that the US will "hit Iran very hard" during the next two months, "until they say they can't take it anymore." Trump orders the military to undertake massive military strikes against Iran, which may begin as early as that weekend and last for several days, in order to push the Iranian regime to negotiate. The DOJ drops their criminal case against former olympian David Hearn for vandalizing the Lincoln Memorial Reflecting Pool. Instead, the DOJ acknowledges that damage to the Reflecting Pool was caused by botched installation from Trump's chosen contractor, Atlantic Industrial Coatings. The following day, Trump criticizes the DOJ's decision on Truth Social.
"Genius" – 3:43 "Half-Life" – 3:59 "Start Again" (Gerry Leonard) – 3:55 "On Her Mind" (Duncan Sheik, Mick Jones) – 4:11 "Such Reveries" – 5:00 "On a High" – 3:36 "Magazines" – 3:47 "For You" – 2:11 "Good Morning!" – 4:04 "Memento" – 3:47 "Shine Inside" – 10:19 Note: The American version of the album features the song "Chimera" after "Shine Inside" as part of the final track (6 minutes and 28 seconds into the track).
The efficacy of dapagliflozin to improve kidney outcomes and reduce cardiovascular death in people with chronic kidney disease was evaluated in a multicenter, double-blind study of 4,304 participants. In February 2023, the EU authorized dapagliflozin for extended use to cover heart failure patients across the full spectrum of left ventricular ejection fraction (LVEF), including those with mildly reduced and preserved ejection fraction.
=== Isomers === Lysergic acid is a chiral compound with two stereocenters. The isomer with inverted configuration at carbon atom 8 close to the carboxyl group is called isolysergic acid. Inversion at carbon 5 close to the nitrogen atom leads to L-lysergic acid and L-isolysergic acid, respectively.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.